Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs
Mikael Nilsson(Uppsala University), Bengt Danielsson(Uppsala University), Kanza Khan(Uppsala University), Bo Blomgren(AstraZeneca (Sweden)), Ann‐Cathrine Johansson(Skåne University Hospital), Kim Kultima(Uppsala University), Ewert Bengtsson(Uppsala University), W. S. Webster(The University of Sydney), Christian Danielsson(Sahlgrenska University Hospital), A.-C. Sköld(AstraZeneca (Sweden)), Joanne Wilson(AstraZeneca (Sweden))
Cited by 16
Related Papers
Faced with inequality: chicken do not have a general dosage compensation of sex-linked genes
|BMC Biology|2007|257
PhenoMeNal: processing and analysis of metabolomics data in the cloud
|GigaScience|2018|147
CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease
|PROTEOMICS - CLINICAL APPLICATIONS|2016|114
Development and Evaluation of Normalization Methods for Label-free Relative Quantification of Endogenous Peptides
|Molecular & Cellular Proteomics|2009|107
Cartilage-binding antibodies induce pain through immune complex–mediated activation of neurons
|The Journal of Experimental Medicine|2019|105